SAILIFENSE7 November 2025

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Sai Life Sciences Limited

07 November 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife

To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306

Sub: Investor Presentation for the quarter and half year ended on 30 September 2025.

Dear Sir/ Madam,

With reference to the above subject, we enclose herewith the Investor Presentation for the quarter and half year ended on 30 September 2025.

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

Runa Karan Company Secretary & Compliance Officer Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

Registered office

# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Sai Life Sciences Limited

Investor Presentation

November 07, 2025

Safe Harbour

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include

words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate",

"intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar

expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of

risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking

statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth

and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income,

cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update

forward-looking statements to reflect events or circumstances after the date thereof.

The CRDMO industry is a Service Business with value drivers different from generic pharma companies

• R&D investments in drug discovery / development program translate to revenue opportunities for CRDMOs – irrespective of whether it receives approval or not

• Stage-gating decisions rest with the innovator (clients)

• Given the multitude of factors involved, the success or failure of a

molecule is never directly attributed to the CRDMO.

• CRDMOs are purely judged by the quality of work they render within the

scope of the defined project

“ As a CRDMO, our value doesn’t hinge on drug approvals - we’re not in the business of binary outcomes. We generate consistent, scalable value through scientific depth, execution reliability, and long term client partnerships.

“

- Krishna Kanumuri, MD & CEO

Executive Summary

Message from Managing Director & CEO

“

We are pleased to report another strong quarter, supported by healthy demand across our discovery,

development, and manufacturing services. The performance was driven by consistent execution, growing

client relationships, and continued traction in late-stage and commercial programs.

As the industry evolves toward more complex and diversified science, we continue to invest in new

modalities, advanced technologies, and capacity expansion to strengthen our long-term competitiveness.

These investments are enabling us to address a broader range of client needs, enhance efficiency across

the value chain, and build deeper scientific capabilities for the future.

Looking ahead, our priorities remain centered on scaling responsibly, advancing technology-led innovation,

and deepening client collaborations. With a strong foundation, expanding infrastructure, and scientific

excellence at the core of our strategy, Sai Life Sciences is well positioned to deliver sustainable growth and

long-term value.“

Mr. Krishna Kanumuri

MD & CEO

Message from Whole-time Director and Chief Financial Officer

“

We sustained our positive momentum this quarter, maintaining growth across our business and keeping Sai Life Sciences firmly on track toward its long-term aspirations.

Total revenue for Q2FY26 stood at ₹537 Cr, up 36% year-on-year, driven by healthy performance across both the CRO and CDMO services. EBITDA for the quarter was ₹156 Cr, with margins at 29%, supported by improved operating leverage, better utilization and continued cost discipline.

We incurred capex of ₹248 Cr during H1, primarily directed toward expanding our R&D capacity, and advancing our offerings in new modalities and technologies. These investments are aligned with our strategy to enhance scientific depth and build scalable capacity to support future growth.

Mr. Siva Chittor

Whole-time Director

& CFO

We remain focused on maintaining financial discipline, driving margin improvement, and deploying capital effectively to sustain long-term, profitable growth.

“

Business Highlights

Deepening Capabilities In New Technologies and Modalities •

“Following-the-molecule” in peptides, the company is complementing existing discovery capability with development and scale-up capability.

•

Successfully completed photo-flow chemistry scale-up at plant scale for a large pharma client

• Working on a large pharma collaboration on ADC chemistry & have completed bioconjugation at the discovery stage for a large pharma client; building OEB-6 labs for

Discovery and CMC to strengthen ADC capabilities.

•

Validating a phosphoramidite process for a commercial oligonucleotide molecule

Quality and Compliance Excellence •

Successfully completed 35 customer and 3 regulatory audits across manufacturing and R&D units in the past 12 months, with zero data integrity deviations and zero

critical observations

Building R&D Capacity

•

Completed phase 2 expansion of Vivarium, Hyderabad R&D Centre - added 12,000 sq. ft. (total 27,000 sq. ft.) with expanded preclinical and assay capabilities

Integrated CMC Partnership •

Partnered with Agility Life Sciences (UK) and Centrix Pharma (UK) to provide end-to-end CMC services from API development to drug product manufacturing and

first-in-human trials

Sustainability & Inclusion Commitments •

Near-term GHG reduction targets were validated by SBTi reinforcing climate-aligned growth

•

Signed UN Women’s Empowerment Principles (WEPs) - strengthens focus on gender equality and inclusive workplace practices

Consolidated Financial Highlights (Quarterly)

Revenue (₹ Cr)

Material Margin (₹ Cr) and Margin (%)

EBITDA (₹ Cr) and Margin (%)

PAT (₹ Cr) and Margin (%)

537

73.7%

73.9%

397

396

36%

YoY

291

36%

YoY

29.0%

156

27.5%

109

15.6%

102%

YoY

43%

YoY

10.5%

Q2FY25

Q2FY26

Q2FY25

Q2FY26

Q2FY25

Q2FY26

Q2FY25

Q2FY26

Q2FY26 Revenue Contribution

CDMO

CRO

66%

34%

•

Revenue for Q2FY26 was ₹537 crore, a 36% increase over ₹396 crore in Q2FY25, driven by strong growth both in CRO and CDMO services

CDMO recorded revenues of ₹352 Cr in Q2FY26, up 37% from ₹240 Cr in Q2FY25

CRO recorded revenues of ₹185 Cr in Q2FY26, up 19% from ₹156 Cr in Q2FY25

EBITDA for Q2FY26 stood at ₹156 Cr compared to ₹109 Cr in Q2FY25, an increase of 43%

EBITDA margin improved by 150 bps to 29% in Q2FY26

PAT for Q2FY26 stood at ₹84 crore.

Consolidated Financial Highlights (Half Yearly)

Revenue (₹ Cr)

Material Margin (₹ Cr) and Margin (%)

EBITDA (₹ Cr) and Margin (%)

PAT (₹ Cr) and Margin (%)

1,034

675

53%

YoY

73.8%

498

72.8%

753

27.2%

281

51%

YoY

20.7%

140

14.0%

144

415%

YoY

101%

YoY

4.1%

H1FY25

H1FY26

H1FY25

H1FY26

H1FY25

H1FY26

H1FY25

H1FY26

H1FY26 Revenue Contribution

CDMO

CRO

64%

36%

•

Revenue for H1FY26 was ₹1,034 crore, a 53% increase over ₹675 crore in H1FY25

CDMO recorded revenues of ₹667 Cr in H1FY26, up 72% from ₹387 Cr in H1FY25

CRO recorded revenues of ₹367 Cr in H1FY26, up 28% from ₹288 Cr in H1FY25

EBITDA for H1FY26 stood at ₹281 Cr compared to ₹140 Cr in H1FY25, an increase of 101%

EBITDA margin expanded by 652 bps YoY to 27.2% in H1FY26

PAT for H1FY26 stood at ₹144 crore.

Invested ₹248 crore in capital expenditure, against a plan of ₹700 Cr for FY26

Sustained Growth Momentum with Expanding Profitability

(Consolidated)

15%

1,217

870

25%

21%

27%

20%

1,465

1,695

1,034

675

FY22

FY23

FY24

FY25

H1FY25

H1FY26

IPO

Revenue (₹ Cr)

EBITDA Margin (%)

Positioned to achieve 15-20% revenue CAGR over 3-5 years & 28 - 30% EBITDA margins in the next 2-3 years

Delivered consistent revenue growth and expanding profitability, with EBITDA margins rising from 15% in FY22 to 25% by FY25 and maintaining positive momentum in H1FY26, keeping Sai on track towards its longer-term growth aspirations

Company Overview

Sai Life Sciences: At a Glance

25+ Years of Expertise

Global Partner of Choice

Expansive Infrastructure

Innovation-Led Growth

Founded in 1999, Sai Life Sciences has transformed into an integrated CRDMO, delivering value across the pharma lifecycle from early discovery to commercial manufacturing

Trusted by 300+ global clients, including 18 of the top 25 global pharma companies across the US, UK, EU, and Japan

World-class R&D and manufacturing facilities across Hyderabad, Bidar, Manchester, and Boston, with ~700 KL of installed capacity

Focused investments in next- gen modalities like Peptides, ADCs, Oligos and TPDs; empowered by digital transformation, automation, and AI/ML to accelerate delivery and differentiation

Key Highlights

25+

Years of experience

(Incorporated in 1999)

One-stop platform for discovery, development and manufacturing

USFDA, PMDA

100% successful track record of

regulatory inspections across our R&D and manufacturing facilities.

Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more

3,400+

Total employees

10+

Years: Enduring customer relationships

300+

Active customers across US, UK, EU, Japan

18/25

of the largest pharmaceutical companies are customers

>65%

18 months

Integrated Drug Discovery Services

Demonstrated time from Hit to IND

Commercial molecules

Phase III/ pre-registration

40+

Programs advanced to IND or Phase I/II/III

Molecules from discovery to market

Global Presence

Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK,

complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India

Sai Facilities Presence

700 KL GMP Manufacturing

Process R&D Lab in Alderley Park

Manchester

Boston

Exploratory Biology Lab in the Cambridge-Boston Life Sciences ecosystem

Bidar

Hyderabad

Global Delivery Model

13-acre Integrated R&D Campus in Genome Valley

Strategically located to combine innovation access, client proximity, and cost efficiency

Our Growth Journey

1999 - 2008

2009 – 2013

2014 – 2018

2019 – 2023

2024 – Present

Founding & Early Biotech Foray

CDMO Pivot

CDMO Consolidation, Biology Foray

Globalization, Scaled-up Integrated CRDMO

Increasing Capacity & Strengthening New-Age Modalities

• Incorporated in 1999; began as a medicinal chemistry partner to US biotech firms

• Expanded into Process R&D and

small-scale manufacturing aligned with the needs of Biotechs clients

• First USFDA approval of Unit IV

• Cleared USFDA & PMDA audits

• Entered global markets: labs in

• Listed on NSE & BSE

• Expanded R&D (Unit II) to enable

at multiple sites

Manchester & Boston

large-scale pharma CDMO services

• Added 100 KL capacity at Unit IV

• Animal facility received AAALAC

accreditation

• Integrated Biology services;

• Commissioned Clean Room,

becoming end-to-end Discovery partner

Amidites, and HPAPI blocks at Unit IV

• Added >120 KL (PB-07) and

>170 KL (PB-08) blocks at Unit IV

• Strategic partnership with Schrödinger to enhance discovery science

• Continued regulatory track record and expansion of global footprint

• Construction underway for new MedChem block with 200 fume hood capacity

• Broke ground for a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early phase peptide development and clinical formulations

• Commenced work on building additional 200kL production capacity at Unit IV, Bidar

A leading CRDMO with scaled operations across both verticals

Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies

Phase 1

DISCOVERY (CRO)

Phase 2

DEVELOPMENT (CRO & CDMO)

Phase 3

MANUFACTURING (CDMO)

• Medicinal Chemistry & Computational

• Process Development & Optimization

• API (Active Pharmaceutical Ingredient)

Drug Discovery

• Biology & Pharmacology Research

• Analytical Development & Validation

• Formulation Development & Stability

Manufacturing

• Technology Transfer & Scale-Up

• DMPK & Toxicology Studies

Studies

• Commercial Production & Global Supply

• Preclinical Research & IND Filing

• Clinical Trial Supplies (Phase I-III)

Chain

• Regulatory Compliance & Quality

Assurance

• Regulatory-Compliant Manufacturing

(US FDA, PMDA, COFEPRIS)

Seamless Integration – One-stop solution from research to commercial production

Regulatory Excellence – Compliant with global standards (US FDA, PMDA, COFEPRIS)

Scalable & Flexible – Supporting emerging biotech & leading pharma companies

Discovery Services (CRO)

Consistent Revenue Growth (₹ Cr)

626

467

497

274

189

FY21

FY22

FY23

FY24

FY25

Customer Split %

67%

62%

33%

FY24

38%

FY25

Pharma

Biotech

Client Stickiness

Dedicated Facility

Modalities Expansion

>65% Revenues from

Among the few CROs

Expanding capabilities

customers in FY23-25

with a dedicated facility

in ADCs, TPDs,

who availed more than

for a global innovator,

Peptides, CGTs, Oligos,

one Discovery services(2)

now scaled up by 30%

and more.

to support growing

demand and deeper

integration.

Notes: (1) Last 5 years (2) Discovery services (including chemistry, biology and/or DMPK services)

Discovery Services: Scaling Innovation, Driving Impact

>65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes

Expanded Core Capabilities

Colocalized & Global Teams

Tech-Enabled Drug Discovery

Specialized Modalities

Next-Gen Preclinical Models

Scaled Chemistry, Biology,

Hyderabad campus and

AI-enabled retrosynthesis

Peptides, ADC payloads,

Organoids and spheroids

DMPK, and In Vivo labs

Boston Biology Lab enable

tools High-throughput

Oligos, TPDs and driving

enable predictive, FDA-

delivering faster, parallelized

seamless collaboration and

Experimentation DMPK

high-value Discovery growth

aligned efficacy and toxicity

research

rapid tech transfer

automation CADD in silico

testing

tools

Technology advancements are transforming Sai’s Discovery platform into a scalable, high-value growth engine

CMC Services (CDMO)

Consistent Revenue Growth (₹ Cr)

•

End-to-End capabilities from IND through to commercialization

Focus on Complex Chemistry, ADC Payloads & Linkers

• Modern, GMP-compliant facilities across UK and India

571

596

760

968

1,068

•

Flexibility to support both small-scale clinical supplies and large-scale commercial production.

Proven track record of commercializing NCEs

• Robust regulatory record with USFDA and PMDA

•

160 Programs in the pipeline across multiple therapy areas

• Clear Regulatory Record: USFDA, PMDA

FY21

FY22

FY23

FY24

FY25

•

At the forefront of digitalization, automation and sustainability

Customer Split %

Business Mix Revenue Contribution – By Therapy (%)

21%

79%

91%

21%

18%

11%

22%

14%

12%

10%

17%

10%

FY24

FY25

Pharma

Biotech

CNS

Infectious Diseases

Cardiovascular Anti Histamine

Oncology

Metabolic Disorders

Genetic Disorders

Dermatology

Immunology

Others

FY24

FY25

Note: Therapy area contribution varies year-to-year based on client portfolio mix and project timelines. Not indicative of overall market trends

New Modalities: Fortifying foundation to build scale

New Modalities Revenue Contribution (%)

FY22

FY23

FY24

FY25

Peptides

Antibody-Drug Conjugates

Complement peptide discovery with process and scale-up facilities for clinical supplies; focus on commercial supply of fragments before evolving to full-scale peptide manufacturing.

Enhancing conjugation in Discovery; upgrading to class 6 containment for end-to-end support. Evaluating clinical conjugation and fill-finish for clinical supply

Oligonucleotides

Lipids

Involved in multiple projects with Pharma from development to commercial; to focus only on making amidites.

Involved in supplying lipids for last few years; looking to expand capacity

Our Strengths

Strategic Growth Levers & Competitive Edge

Expanding Capacity & Capabilities

Technology-Driven Efficiency

Talent & Innovation Culture

Deeper Customer Engagement

Global Footprint, Local Advantage

Quality & Sustainability Leadership

Information Technology - Driven Excellence: Digitization & Beyond

Digitization

2017 onwards

Digitalization

2022 onwards

Digital Transformation

2023 onwards

Converting data, documents and processes from paper/ analog to digital

Use of digitized data for effective monitoring through visual interactive dashboards.

integration of digital technologies into all aspects of business operations

R&D and Mfg processes progressively digitized to current levels of 85% digitization

Interactive Business Intelligence dashboards created using real-time data across functions and use cases.

Leveraging large data sets with AIML models to create prediction models.

• GMP Pro and ELN implementation • QR Code & Label Management • Learning Management System • Audit Management System • Laboratory Information Management System • Validation Life Cycle Management System

• Batch Quality, Yield, Experiments, Equipment

Occupancy, Staffing status, QMS, etc.

• Digital Transformation Initiatives • AI/ML - Manufacturing Process Prediction

Model

Looking Ahead

• • • •

Digitization process expected to be complete by 2027 Continued adoption of BI models to aid faster decision-making AI/ML model proof-of-concept outcome to emerge in 2026. Based on results, further integration into operations will be undertaken.

Global-Standard Operations, End-to-End

Quality Assurance

Sustainability Leadership

Safety & EHS Leadership

• 285+ QA/QC professionals

• 89% renewable energy at Bidar

• Embedded Process Safety from

across sites

site

• Integrated e-systems: LIMS, e-

• Zero Liquid Discharge: water-

QMS

neutral ops

• QA independent; reports to

• Carbon roadmap approved by

CEO

• Audited by USFDA, EMA, PMDA, Indian regulators

• Focus on data integrity & global

compliance

SBTi

• Low-emission logistics via DHL

quote to execution phase; rigorous lifecycle safety assessments.

• Plant Intermediates areas & lab fume cupboards validated down to 1 µcg/ m3 containment

• First Indian company to join the PSCI membership; >30 PSCI Audits over the past 7 years

• Silver rating by EcoVadis

Key Drivers for Growth

Scaling Capacity & Infrastructure

Diversifying Portfolio

Scientific & Talent Leadership

•

The company continue to make strategic capital investments in line with its annual capex plan of ~ ₹700 Cr for FY26 to enhance manufacturing and R&D infrastructure, including development of a second manufacturing site in Hyderabad.

These strategic investments will nearly double Sai’s overall manufacturing capacity by FY27, while diversifying its footprint and reducing concentration risk

•

36 active molecules* –30 commercial, with 6 Phase III / pre registration

160 in early phase development

Established model for a dedicated partnerships

Average tenure of large pharma relationships is ~10 years

200+ clients, 60+ integrated collaboration under discovery

•

Driving global program transfers to India across discovery, development & manufacturing

Rapidly expanding leadership bench with experts from top CDMOs and global pharma

Strengthening capabilities in new modalities, enabling pipeline expansion and stickier client relationships

Building future-ready teams aligned to Sai’s scale-up and innovation roadmap

* Excluding molecules under destocking and low value molecules with limited potential

Expansion Plans

Capacity Expansion Underway: Scaling from 700 KL to 1,150 KL by 2026

PB 11 Intermediate block & unit 06 animal health API block

PB 14 & 15 Intermediate Block in 5.9 Acre U4 ext

PB 10 high potency & PB 12 amidite blocks

1,150

PB08 Intermediate PB09 clean room blocks

700

450

475

PB07 Intermediate Block

230

2017

2021

2023

2025

2026

Unit 3 & Unit 4 Blocks 1-6

105

2013

2009

2011

Reactor capacity in KL

1,400

1,200

1,000

800

600

400

200

CMC Process R&D Block

Sai Life Sciences has commenced construction of a new CMC Process R&D Center at its Hyderabad campus, targeted for completion by September 2026.

The facility will double Process R&D capacity. Designed to support both FTE and DPC engagement models, it will offer flexible collaboration for global

innovators across early to late-stage CMC programs.

▪ Specialized labs for peptides and Amidites

▪ Kilo Lab for early clinical supplies

▪ NCE Formulation Development & Early Phase Clinical Supplies

▪ Designed to meet OEL 4 (1 µg/m3) band

▪ Process R&D lab and Scale up Lab

▪ ~140 process chemistry fume hoods with satellite analytical lab

▪ Buildup area ~100K Sq.Ft across 5 floors with Green building

Certification

▪

25,000 sft of Analytical Lab under a single roof

Note: FTE- Full Time Equivalent. DPC- Discovery Process Chemistry

Industry Overview

Global CRDMO Industry Set to Cross USD 300 Bn by 2028

Global CRDMO Market (USD Bn)

Global CRDMO Market by Modality (USD Bn)

303

196

127

225

Large molecule

Small molecule

153

106

2018

2023

2028E

2018

2023

2028E

• Global CRDMO market projected to reach USD 303 Bn by 2028 (9% CAGR 2023-2028)

•

50%+ of pharma R&D budgets outsourced to CRDMOs, driving structural growth

• Biologics, peptides, and oligonucleotides expected to drive ~40% of total growth by 2028

With growing investments

in Peptides, Oligos &

ADCs, Sai Life Sciences is

positioned to capture

growth in the fastest-

expanding CRDMO

segments globally

•

Large molecule CRDMO segment growing fastest (12% CAGR 2023 - 28), supported by biologics demand

• Asia-Pacific market projected to grow at 12% CAGR (2023–28) - the fastest among all regions, outpacing Europe (10%) and North

America (5%)

Source: Frost & Sullivan

India Rising as a Strategic CRDMO Hub

Indian CRDMO Market (USD Bn)

Global CRDMO Market by Modality (USD Bn)

Large molecule

Small molecule

2018

2023

2028E

2018

2023

2028E

Sai Life Sciences is

scaling capacity,

innovation, and specialty

modalities to leverage

India’s rising global

CRDMO share and China-

to-India outsourcing shift.

•

Indian CRDMO industry is among the fastest-growing worldwide, projected to grow at 14% CAGR (2023–28)

• By 2028, CDMO is expected to contribute ~75% of India’s USD 14 Bn CRDMO market, growing to USD 11 Bn, while CRO expands to

USD 3 Bn

• Cost efficiency (30–40%) with global-standard quality is making India the preferred outsourcing destination for pharma sponsors

Source: Frost & Sullivan

Annexure

Consolidated Statement of Profit and Loss

Particulars (₹ Cr)

Revenue from operations

Other income

Total income

Expenses

Cost of materials consumed and changes in inventories

Employee benefits expense

Other expenses

Forex (gain)/loss

EBITDA

EBITDA Margin

Finance costs

Depreciation and amortisation expense

Profit before tax

Tax expense

Profit after tax

Q2FY26

Q1FY26

Q2FY25

H1FY26

H1FY25

537

543

140

163

(10)

156

29%

112

496

502

141

161

(4)

125

25%

396

399

104

135

(6)

109

27%

1,034

1045

281

323

162

(14)

281

27%

193

144

675

682

177

265

105

(11)

140

21%

FY25

1695

1712

466

549

274

(19)

425

25%

139

228

170

Consolidated Balance Sheet

Assets (₹ Cr)

Non Current Assets

Property, Plant, and Equipment

Right of Use of Assets

Capital Work in Progress

Intangible Assets

Financial assets

- Investments

- Other Financial Assets

Deferred Tax Assets

Non Current Tax Assets (Net)

Other Non-current Assets

Total Non-current Assets

Current Assets

Inventories

Financial Assets

- Trade Receivables

- Cash and Bank Balances

- Other Financial Assets

Other Current Assets

Total Current Assets

TOTAL Assets

Mar 25

Sept 25

Equity and Liabilities (₹ Cr)

Mar 25

Sept 25

1,185

1,337

Equity Share Capital

Equity

292

124

276

115

Reserves and Surplus

Total Equity

Non Current Liabilities Financial Liabilities - Lease Liabilities Provisions Deferred Tax Liabilities (Net)

Total Non-current Liabilities

1,655

1,842

119

355

464

487

1,505

3,160

122

492

306

509

1,489

3,331

Current Liabilities

Financial Liabilities

- Borrowings

- Lease Liabilities

- Trade Payables

- Other Current Financial Liabilities

Other Current Liabilities

Provisions

Current Tax Liabilities (Net)

Total Current Liabilities

TOTAL Equity and Liabilities

2,108

2,128

2,249

2,270

165 23 111 299

129

323

128

732

`146 30 110 286

215

245

133

775

3,160

3,331

Awards Certificates & Accreditations

ISO 14001:2015, ISO 45001:2018 & ISO 50001:2018 certification

Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013

Affiliations with Leading Industry organizations:

Signatory of United Nations Global Compact (UNGC)

Eco Vadis Silver Medal for Sustainability

CII-SR EHS Excellence Award for 5 Years

GSK’s Environmental Sustainability Supplier award 2021 in ‘Primary Manufacturing’ category

Glossary

APIs

Biotechs

Active pharmaceutical ingredients

Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs

Blockbuster End Molecules Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023

CDSCO

CMC / CDMO

CMO

Central Drug Standards Control Organization, India

Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization

Contract Manufacturing Organization

COFEPRIS Mexico

Federal Commission for the Protection against Sanitary Risk of Mexico

CRDMO

CRO

DMPK

GATT

Contract Research, Development, And Manufacturing Organization

Contract Research Organization

Drug metabolism and pharmacokinetics

General Agreement on Tariffs and Trade

Generic drugs

Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires

Innovation Clusters/Hubs

Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs

Innovator Drugs

Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use

Large Molecule

Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes

Large Pharma Companies

Pharma companies with revenues > USD 10 billion

Mid Pharma Companies

Pharma companies with revenues in range of USD 500 million to USD 10 billion

NCE

PMDA

Small Molecule

New chemical entities

Pharmaceuticals and Medical Devices Agency, Japan

Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes

Small Pharma Companies

Pharma companies with revenues lower than USD 500 million

TRIPS

UNIT IV

USFDA

Trade-Related Aspects of Intellectual Property Rights

Manufacturing facility at Bidar

United States Food and Drug Administration

Thank You

For more details please contact:

Investorrelation@sailife.com

L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.

← All Transcripts SAILIFE Stock Page →

Sai Life Sciences Limited has informed the Exchange about Investor Presentation

Market Movers